These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 33073806)
41. Quantification and Assessment of the Chemical Form of Residual Gadolinium in the Brain After Repeated Administration of Gadolinium-Based Contrast Agents: Comparative Study in Rats. Frenzel T; Apte C; Jost G; Schöckel L; Lohrke J; Pietsch H Invest Radiol; 2017 Jul; 52(7):396-404. PubMed ID: 28125438 [TBL] [Abstract][Full Text] [Related]
42. Comparative study of the physicochemical properties of six clinical low molecular weight gadolinium contrast agents. Laurent S; Elst LV; Muller RN Contrast Media Mol Imaging; 2006; 1(3):128-37. PubMed ID: 17193689 [TBL] [Abstract][Full Text] [Related]
43. Gd-TEMDO: Design, Synthesis, and MRI Application. Boltjes A; Shrinidhi A; van de Kolk K; Herdtweck E; Dömling A Chemistry; 2016 May; 22(22):7352-6. PubMed ID: 26991633 [TBL] [Abstract][Full Text] [Related]
44. GdIII complexes with fast water exchange and high thermodynamic stability: potential building blocks for high-relaxivity MRI contrast agents. Laus S; Ruloff R; Tóth E; Merbach AE Chemistry; 2003 Aug; 9(15):3555-66. PubMed ID: 12898682 [TBL] [Abstract][Full Text] [Related]
45. Synthesis and relaxivity studies of a tetranuclear gadolinium(III) complex of DO3A as a contrast-enhancing agent for MRI. Jebasingh B; Alexander V Inorg Chem; 2005 Dec; 44(25):9434-43. PubMed ID: 16323930 [TBL] [Abstract][Full Text] [Related]
46. Hepatic abscesses. Magnetic resonance imaging findings using gadolinium-BOPTA. Runge VM; Wells JW; Williams NM Invest Radiol; 1996 Dec; 31(12):781-8. PubMed ID: 8970881 [TBL] [Abstract][Full Text] [Related]
48. Comparative transmetallation kinetics and thermodynamic stability of gadolinium-DTPA bis-glucosamide and other magnetic resonance imaging contrast media. Puttagunta NR; Gibby WA; Puttagunta VL Invest Radiol; 1996 Oct; 31(10):619-24. PubMed ID: 8889650 [TBL] [Abstract][Full Text] [Related]
49. Pharmacokinetics of Gd(DO3A-Lys) and MR imaging studies in an orthotopic U87MG glioma tumor model. Chandrasekharan P; Yang CT; Nasrallah FA; Tay HC; Chuang KH; Robins EG Contrast Media Mol Imaging; 2015; 10(3):237-44. PubMed ID: 25612157 [TBL] [Abstract][Full Text] [Related]
50. Gadolinium Retention, Brain T1 Hyperintensity, and Endogenous Metals: A Comparative Study of Macrocyclic Versus Linear Gadolinium Chelates in Renally Sensitized Rats. Rasschaert M; Emerit A; Fretellier N; Factor C; Robert P; Idée JM; Corot C Invest Radiol; 2018 Jun; 53(6):328-337. PubMed ID: 29329151 [TBL] [Abstract][Full Text] [Related]
51. An intravascular MRI contrast agent based on Gd(DO3A-Lys) for tumor angiography. Yang CT; Chandrasekharan P; He T; Poh Z; Raju A; Chuang KH; Robins EG Biomaterials; 2014 Jan; 35(1):327-36. PubMed ID: 24138829 [TBL] [Abstract][Full Text] [Related]
52. Relaxometry studies of a highly stable nanoscale metal-organic framework made of Cu(II), Gd(III), and the macrocyclic DOTP. Carné-Sánchez A; Bonnet CS; Imaz I; Lorenzo J; Tóth E; Maspoch D J Am Chem Soc; 2013 Nov; 135(47):17711-4. PubMed ID: 24215474 [TBL] [Abstract][Full Text] [Related]
53. A new class of Gd-based DO3A-ethylamine-derived targeted contrast agents for MR and optical imaging. Mishra A; Pfeuffer J; Mishra R; Engelmann J; Mishra AK; Ugurbil K; Logothetis NK Bioconjug Chem; 2006; 17(3):773-80. PubMed ID: 16704217 [TBL] [Abstract][Full Text] [Related]
54. Inulin as a carrier for contrast agents in magnetic resonance imaging. Corsi DM; Elst LV; Muller RN; van Bekkum H; Peters JA Chemistry; 2001 Jan; 7(1):64-71. PubMed ID: 11205027 [TBL] [Abstract][Full Text] [Related]
55. Simultaneous acquisition of MR angiography and diagnostic images of abdomen at view-sharing multiarterial phases and comparing the effect of two different contrast agents. Noda Y; Goshima S; Namimoto T; Shinkawa N; Nakagawa M; Kajita K; Kawada H; Kawai N; Tanahashi Y; Matsuo M; Bae KT; Hirai T; Yamashita Y J Magn Reson Imaging; 2018 Jul; 48(1):102-110. PubMed ID: 29247585 [TBL] [Abstract][Full Text] [Related]
56. Prediction of q-values and conformations of gadolinium chelates for magnetic resonance imaging. Castonguay LA; Treasurywala AM; Caulfield TJ; Jaeger EP; Kellar KE Bioconjug Chem; 1999; 10(6):958-64. PubMed ID: 10563764 [TBL] [Abstract][Full Text] [Related]
57. Comparison of gadolinium Cy2DOTA, a new hepatobiliary agent, and gadolinium HP-DO3A, an extracellular agent, in healthy liver and metastatic disease. Runge VM; Wells JW; Williams NM Invest Radiol; 1995 Feb; 30(2):123-30. PubMed ID: 7782188 [TBL] [Abstract][Full Text] [Related]
58. Aggregation in amphiphilic macrocycle-substituted Gd(3+) DOTA-type chelates is affected by the regiochemistry of substitution. Webber BC; Cassino C; Botta M; Woods M Inorg Chem; 2015 Mar; 54(5):2085-7. PubMed ID: 25692481 [TBL] [Abstract][Full Text] [Related]
59. Comprehensive evaluation of the physicochemical properties of Ln(III) complexes of aminoethyl-DO3A as pH-responsive T(1) -MRI contrast agents. Baranyai Z; Rolla GA; Negri R; Forgács A; Giovenzana GB; Tei L Chemistry; 2014 Mar; 20(10):2933-44. PubMed ID: 24590497 [TBL] [Abstract][Full Text] [Related]
60. Gadolinium(III) complexes as MRI contrast agents: ligand design and properties of the complexes. Hermann P; Kotek J; Kubícek V; Lukes I Dalton Trans; 2008 Jun; (23):3027-47. PubMed ID: 18521444 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]